Zura Bio Limited (NASDAQ:ZURA) Receives $11.60 Average PT from Brokerages

Shares of Zura Bio Limited (NASDAQ:ZURA) have been given an average recommendation of “Moderate Buy” by the seven analysts that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $11.60.

ZURA has been the subject of a number of research analyst reports. Chardan Capital upped their target price on Zura Bio from $10.00 to $11.00 and gave the company a “buy” rating in a research report on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zura Bio in a research report on Friday, January 9th. Wedbush started coverage on Zura Bio in a report on Monday, February 9th. They issued an “outperform” rating and a $15.00 price objective for the company. Finally, Oppenheimer lowered their target price on shares of Zura Bio from $16.00 to $15.00 and set an “outperform” rating on the stock in a research report on Friday, March 20th.

Insider Transactions at Zura Bio

In related news, major shareholder Ai Biotechnology Llc acquired 2,000,000 shares of the firm’s stock in a transaction on Thursday, February 26th. The stock was bought at an average cost of $6.25 per share, with a total value of $12,500,000.00. Following the transaction, the insider owned 6,552,725 shares of the company’s stock, valued at $40,954,531.25. The trade was a 43.93% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 22.10% of the company’s stock.

Institutional Investors Weigh In On Zura Bio

Several large investors have recently modified their holdings of the stock. Suvretta Capital Management LLC raised its holdings in Zura Bio by 1.7% during the fourth quarter. Suvretta Capital Management LLC now owns 5,567,001 shares of the company’s stock worth $29,171,000 after purchasing an additional 94,110 shares in the last quarter. VR Adviser LLC raised its stake in shares of Zura Bio by 15.4% during the 4th quarter. VR Adviser LLC now owns 5,345,115 shares of the company’s stock worth $28,008,000 after buying an additional 713,899 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Zura Bio by 78.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,659,951 shares of the company’s stock worth $4,893,000 after buying an additional 2,052,732 shares in the last quarter. Braidwell LP lifted its holdings in shares of Zura Bio by 28.6% in the 4th quarter. Braidwell LP now owns 3,180,389 shares of the company’s stock valued at $16,665,000 after buying an additional 707,583 shares during the period. Finally, Affinity Asset Advisors LLC boosted its stake in shares of Zura Bio by 42.3% in the fourth quarter. Affinity Asset Advisors LLC now owns 1,813,671 shares of the company’s stock valued at $9,504,000 after buying an additional 539,320 shares in the last quarter. Hedge funds and other institutional investors own 61.14% of the company’s stock.

Zura Bio Stock Performance

NASDAQ:ZURA opened at $5.38 on Friday. The stock has a 50-day simple moving average of $6.18 and a 200-day simple moving average of $4.61. The stock has a market cap of $349.81 million, a P/E ratio of -5.08 and a beta of 0.18. Zura Bio has a 1 year low of $0.97 and a 1 year high of $7.44.

Zura Bio (NASDAQ:ZURA) last announced its quarterly earnings results on Thursday, March 19th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.31). On average, equities research analysts predict that Zura Bio will post -0.65 EPS for the current year.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.